Literature DB >> 2731980

Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica.

E Wachter1, V Brade.   

Abstract

Effector mechanisms resulting from alternative complement pathway (ACP) activation cannot act efficiently against Yersinia enterocolitica serotype O3, as indicated by poor C3 to C9 consumption and by survival in EGTA (ethyleneglycoldiaminetetraacetic acid) Mg-serum. These results were not influenced by the lack or presence of plasmid-encoded outer membrane proteins or lipopolysaccharides (LPS) with different amounts of side chains or by treatment of the bacteria with pronase or neuraminidase. Surface modulation of Y. enterocolitica with polyclonal immunoglobulin G or the immunoglobulin G fragments F(ab')2 and Fab always converted Y. enterocolitica to a high ACP activator, with strong C3 to C9 consumption and surface deposition of activated C3. Killing of Y. enterocolitica as a result of antibody-mediated ACP activation was observed only with bacteria grown at 22 degrees C but not with bacteria from 37 degrees C cultures. The expression of complement resistance in Y. enterocolitica grown at 37 degrees C was not influenced by the presence or absence of plasmids. Using different monoclonal antibodies (MAb), we found that MAb with LPS specificity mediated ACP activation, whereas MAb specific for different plasmid-encoded outer membrane proteins were ineffective, despite surface binding. These results suggest a major inhibitory role of LPS on ACP activation which was neutralized by LPS-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731980      PMCID: PMC313831          DOI: 10.1128/iai.57.7.1984-1989.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Expression of the temperature-inducible outer membrane proteins of yersiniae.

Authors:  I Bölin; D A Portnoy; H Wolf-Watz
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

2.  Activation of complement via the alternative pathway.

Authors:  M K Pangburn
Journal:  Fed Proc       Date:  1983-01

3.  Yersinia enterocolitica in two dogs.

Authors:  M Papageorges; R Higgins; Y Gosselin
Journal:  J Am Vet Med Assoc       Date:  1983-03-15       Impact factor: 1.936

4.  Plasmid-mediated and temperature-regulated surface properties of Yersinia enterocolitica.

Authors:  R J Martinez
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

5.  Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.

Authors:  M S Edwards; D L Kasper; H J Jennings; C J Baker; A Nicholson-Weller
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

6.  Plasmids of human strains of Yersinia enterocolitica: molecular relatedness and possible importance for pathogenesis.

Authors:  J Heesemann; C Keller; R Morawa; N Schmidt; H J Siemens; R Laufs
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

7.  [Sugar composition of the lipopolysaccharide and ultrastructural study of the outer membrane of Yersinia enterocolitica (author's transl)].

Authors:  G Acker; K Wartenberg; W Knapp
Journal:  Zentralbl Bakteriol A       Date:  1980

8.  Vwa+ phenotype of Yersinia enterocolitica.

Authors:  R D Perry; R R Brubaker
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.

Authors:  K A Joiner; R C Goldman; C H Hammer; L Leive; M M Frank
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

10.  The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus.

Authors:  M S Edwards; A Nicholson-Weller; C J Baker; D L Kasper
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

View more
  12 in total

1.  Mechanism of YadA-mediated serum resistance of Yersinia enterocolitica serotype O3.

Authors:  D Pilz; T Vocke; J Heesemann; V Brade
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

2.  Yersinia pseudotuberculosis uses Ail and YadA to circumvent neutrophils by directing Yop translocation during lung infection.

Authors:  Michelle K Paczosa; Michael L Fisher; Francisco J Maldonado-Arocho; Joan Mecsas
Journal:  Cell Microbiol       Date:  2013-11-03       Impact factor: 3.715

3.  Modulation of complement activity in vitro and in vivo by Yersinia wild and mutant strains.

Authors:  M Yordanov; E Golkocheva; H Najdenski
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

4.  Role of YadA, Ail, and Lipopolysaccharide in Serum Resistance of Yersinia enterocolitica Serotype O:3.

Authors:  Marta Biedzka-Sarek; Reija Venho; Mikael Skurnik
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

5.  Legionella pneumophila lipopolysaccharide activates the classical complement pathway.

Authors:  C S Mintz; D R Schultz; P I Arnold; W Johnson
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

6.  Role of the YadA protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules.

Authors:  B China; M P Sory; B T N'Guyen; M De Bruyere; G R Cornelis
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

7.  Mutations affecting lipopolysaccharide enhance ail-mediated entry of Yersinia enterocolitica into mammalian cells.

Authors:  D E Pierson
Journal:  J Bacteriol       Date:  1994-07       Impact factor: 3.490

8.  Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans.

Authors:  Gayle M Boxx; Casey T Nishiya; Thomas R Kozel; Mason X Zhang
Journal:  Mol Immunol       Date:  2008-11-26       Impact factor: 4.407

9.  Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway.

Authors:  M X Zhang; T R Kozel
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

10.  Lipopolysaccharide O side chain of Yersinia enterocolitica O:3 is an essential virulence factor in an orally infected murine model.

Authors:  A al-Hendy; P Toivanen; M Skurnik
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.